Jaguar LAA acquires Johnson & Johnson's Laminar atrial fibrillation device assets

Jaguar LAA, a newly formed medtech company, announced it has purchased assets related to Johnson & Johnson's Laminar atrial fibrillation device program.

The Laminar technology is a catheter‑based system designed to close the left atrial appendage with minimal device exposure, aiming to lower stroke risk in patients with atrial fibrillation.

The transaction price was not disclosed, and the deal also moves the development team to Jaguar LAA, allowing the program to continue under an independent entity.

Early‑stage investor Santé Ventures, which backs Jaguar LAA, has raised $330 million for broader biotech, medtech, and digital health investments.

Jaguar’s chief medical officer said the company will pursue further development of the LAA closure approach as a new treatment option for atrial fibrillation.